{"nctId":"NCT03273387","briefTitle":"The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension","startDateStruct":{"date":"2017-09-10","type":"ACTUAL"},"conditions":["Precapillary Pulmonary Hypertension"],"count":26,"armGroups":[{"label":"Sugar pill","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral capsule"]},{"label":"trimetazidine","type":"EXPERIMENTAL","interventionNames":["Drug: Trimetazidine"]}],"interventions":[{"name":"Trimetazidine","otherNames":["Trizedon MR"]},{"name":"Placebo oral capsule","otherNames":["sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pre-capillary Pulmonary Hypertension patients assessed by right heart catheterization\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient belonging to post-capillary, Isolated post-capillary, or combined post -capillary and pre-capillary pulmonary hypertension according to 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\n* Moderate to severe chronic pulmonary obstructive disease\n* Right Ventricular Ejection Fraction \\> 45% assessed by cardiac magnetic resonance.\n* Documented left ventricular dysfunction with left ventricular ejection fraction \\< 50% assessed by cardiac magnetic resonance.\n* Severe renal impairment (Serum creatinine \\> 2.5 mg/dL, eGFR \\< 30ml/min/1.73 m\\^2, or routine dialysis treatment).\n* Malignant arrhythmia such as total atrioventricular block or ventricular fibrillation or unstable ventricular tachycardia.\n* Patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit\n* Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements\n* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements\n* Females who are lactating or pregnant or those who plan to become pregnant during the study\n* Known Parkinson disease\n* Known hypersensitivity to any of the drug formulation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in Right Ventricular Ejection Fraction (RVEF %) After 3 Months Intervention","description":"Right ventricular ejection fraction (RVEF %) assessed by Cardiac MRI at 3 months intervention minus with RVEF at baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.6"},{"groupId":"OG001","value":"3.9","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Changes in Cardiac Fibrosis After 3 Months Intervention","description":"Native T1 mapping (ms) assessed by Cardiac MRI at 3 months intervention minus with Native T1 at baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":"555"},{"groupId":"OG001","value":"190","spread":"538"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":"677"},{"groupId":"OG001","value":"371","spread":"670"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"294","spread":"618"},{"groupId":"OG001","value":"-123","spread":"645"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"287","spread":"744"},{"groupId":"OG001","value":"-194","spread":"487"}]}]}]},{"type":"SECONDARY","title":"Changes in Functional Capacity After 3 Month Intervention","description":"Functional capacity assessed by SF-36 score after 3 month intervention minus with functional capacity at baseline.\n\nSF-36 functional capacity score scale 0 to 100 with better functional capacity along with higher score.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.73","spread":"3.72"},{"groupId":"OG001","value":"11.5","spread":"5.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":13},"commonTop":["paresthesia","nausea","musculoskeletal angina"]}}}